We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AKM OLMESARTAN AMLODIPINE (Pharmacor Pty Ltd)
Product name
AKM OLMESARTAN AMLODIPINE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
148 working days (255)
Active ingredients
amlodipine besilate; olmesartan medoxomil
Registration type
New generic medicine
Indication
AKM OLMESARTAN AMLODIPINE (tablets) is indicated for the treatment of hypertension. Treatment should not be initiated with this fixed-dose combination.